Drugs / Ulimorelin
Ulimorelin
also known as
TZP-101 · LP101 · TZP-101 FREE BASE · ULIMORELIN HYDROCHLORIDE · Ulimorelin hydrochloride monohydrate · Ulimorelina · Ulimoreline
Small molecule targets GHSR via activation
Trials 10
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials | ||||||
| Phase 1 | NCT02993055 | Jan → Nov 2015 | — | Lyric Pharmaceuticals | Completed | Mixed |
| Phase 1 | NCT01668199 | Feb 2012 | ileus | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT01405612 | Jun → Jul 2011 | digestive system disorder | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT01405599 | Jun → Oct 2011 | digestive system disorder | Norgine | Completed | No outcome recorded |
| Phase 1 | NCT00639808 | Aug 2006 → Jul 2007 | diabetes mellitus, gastroparesis | Tranzyme, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02784392 | Oct 2016 → Mar 2018 | — | Lyric Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00612014 | Oct 2007 → Feb 2009 | diabetes mellitus, gastroparesis | Tranzyme, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT00617552 | Jul 2007 → Jul 2008 | ileus | Tranzyme, Inc. | Completed | No outcome recorded |
| Phase 32 trials · 2 missed | ||||||
| Phase 3 | NCT01296620 | Feb 2011 → Mar 2012 | intestinal dysmotility syndrome | Tranzyme, Inc. | Completed | Missed primary |
| Phase 3 | NCT01285570 | Jan 2011 → Jan 2012 | intestinal motility disease | Tranzyme, Inc. | Completed | Missed primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT01710982 Comparator | Feb → Apr 2012 | ileus | Norgine | Completed | No outcome recorded |
Evidence & citations 12 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ulimorelin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01405612 ↗ |
| Known as | LP101 | “Intravenous Ulimorelin (LP101)” NCT02784392 ↗1“Ulimorelin (LP101)” NCT02993055 ↗ |
| Known as | TZP-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01668199 ↗ |
| Known as | TZP-101 FREE BASE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1963249 ↗ |
| Known as | ULIMORELIN HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL1963249 ↗ |
| Known as | Ulimorelin hydrochloride monohydrate | ChEMBL registry synonym — accepted as the source's own label CHEMBL1963249 ↗ |
| Known as | Ulimorelina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1963249 ↗ |
| Known as | Ulimoreline | ChEMBL registry synonym — accepted as the source's own label CHEMBL1963249 ↗ |
| Action | Activate | “a small molecule ghrelin agonist” PMID 32017341 ↗ Feb 20201“Ghrelin receptor agonist” CHEMBL1963249 ↗ |
| Modality | Small molecule | “Ulimorelin is a first-in-class new chemical entity.” NCT01405612 ↗ |
| Route | Intravenous | “40 micrograms/kg iv 2ml/minute for 30 minutes” NCT00612014 ↗ |
| Target | GHSR | “Ghrelin receptor agonist” CHEMBL1963249 ↗ |